Pneumagen develops glycan targeted carbohydrate binding modules (CBMs) for respiratory tract infections ) and cancer.
Pneumagen has raised $10.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in June 2023.
Pneumagen's investors include Scottish Enterprise, Equity Gap, Esperante Ventures, Thairm Bio, Scottish Investment Bank.
Pneumagen is headquartered in Saint Andrews, United Kingdom.
Pneumagen develops glycan targeted carbohydrate binding modules (CBMs) for respiratory tract infections ) and cancer.
Pneumagen is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Pneumagen — Funding & Investors." VCBacked, June 1, 2023, https://www.vcbacked.co/company/pneumagen. Accessed October 4, 2026.
VCBacked. (2023). Pneumagen — Funding & Investors. Retrieved October 4, 2026, from https://www.vcbacked.co/company/pneumagen
{{cite web |title=Pneumagen — Funding & Investors |url=https://www.vcbacked.co/company/pneumagen |website=VCBacked |access-date=October 4, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated